LDN-27219
LDN-27219 is a reversible, slow-binding inhibitor of TGase. LDN-27219 inhibits human TGase with an IC50 value of 0.6 μM. LDN-27219 effectively decreases blood pressure and induces vasodilation, it can be used for the research of cardiovascular disease[1][2].
Product Specifications
CAS Number
[312946-37-5]
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Glutaminase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Others; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/LDN-27219.html
Purity
99.64
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(C2=CC=CC=C2)C(SCC(NN)=O)=NC3=C1C(C4=CC=CC=C4)=CS3
Molecular Formula
C20H16N4O2S2
Molecular Weight
408.50
Precautions
H315, H319, H335
References & Citations
[1]Case A, et al. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Biochemistry. 2007 Jan 30;46 (4) :1106-15.|[2]Pinilla E, et al. Transglutaminase 2 Inhibitor LDN 27219 Age-Dependently Lowers Blood Pressure and Improves Endothelium-Dependent Vasodilation in Resistance Arteries. Hypertension. 2021 Jan;77 (1) :216-227.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
040913-PE 200 µL
RBPJ, NT (RBPJ, IGKJRB, IGKJRB1, RBPJK, RBPSUH, Recombining binding protein suppressor of hairless, CBF-1, J kappa-recombination signal-binding protein, RBP-J kappa, Renal carcinoma antigen NY-REN-30) (PE) discontinued
Ask
View Details 
GTR15265296 1 Vial
Lentiviral mouse Ipo4 shRNA (UAS) - Lentiviral mouse Ipo4 shRNA (UAS, RFP) (100)
Ask
View Details 